CA3167346A1 - Vaccin et methodes de depistage et de prevention de la filariose - Google Patents

Vaccin et methodes de depistage et de prevention de la filariose Download PDF

Info

Publication number
CA3167346A1
CA3167346A1 CA3167346A CA3167346A CA3167346A1 CA 3167346 A1 CA3167346 A1 CA 3167346A1 CA 3167346 A CA3167346 A CA 3167346A CA 3167346 A CA3167346 A CA 3167346A CA 3167346 A1 CA3167346 A1 CA 3167346A1
Authority
CA
Canada
Prior art keywords
protein
cells
seq
antibodies
immunogenic composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3167346A
Other languages
English (en)
Inventor
Ramaswamy Kalyanasundaram
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Illinois
Original Assignee
University of Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/790,277 external-priority patent/US11370814B2/en
Application filed by University of Illinois filed Critical University of Illinois
Publication of CA3167346A1 publication Critical patent/CA3167346A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0003—Invertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une composition immunogène multivalente servant à immuniser un animal contre la filariose. Dans certains modes de réalisation, les antigènes de la composition immunogène multivalente sont basés sur une ou des protéines, sur l'ADN ou sur une combinaison de ceux-ci. Une méthode et un kit permettant de détecter un nématode filarien et de déterminer l'efficacité d'un vaccin sont également décrits.
CA3167346A 2020-02-13 2021-02-12 Vaccin et methodes de depistage et de prevention de la filariose Pending CA3167346A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16/790,277 US11370814B2 (en) 2010-11-15 2020-02-13 Vaccine and methods for detecting and preventing filariasis
US16/790,277 2020-02-13
PCT/US2021/017813 WO2021163448A2 (fr) 2020-02-13 2021-02-12 Vaccin et méthodes de dépistage et de prévention de la filariose

Publications (1)

Publication Number Publication Date
CA3167346A1 true CA3167346A1 (fr) 2021-08-19

Family

ID=77295222

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3167346A Pending CA3167346A1 (fr) 2020-02-13 2021-02-12 Vaccin et methodes de depistage et de prevention de la filariose

Country Status (7)

Country Link
EP (1) EP4103225A2 (fr)
JP (1) JP2023513607A (fr)
CN (1) CN115209916A (fr)
AU (1) AU2021218797A1 (fr)
BR (1) BR112022015994A2 (fr)
CA (1) CA3167346A1 (fr)
WO (1) WO2021163448A2 (fr)

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3740421A (en) 1966-09-19 1973-06-19 Basf Wyandotte Corp Polyoxyethylene-polyoxypropylene aqueous gels
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
US5207987A (en) 1990-05-21 1993-05-04 Pb Diagnostic Systems Inc. Temperature controlled chamber for diagnostic analyzer
US5604105B1 (en) 1990-10-12 1999-08-24 Spectral Diagnostics Inc Method and device for diagnosingand distinguishing chest pain in early onset thereof
US5639876A (en) * 1991-02-12 1997-06-17 Heska Corporation Nucleic acid molecules encoding novel parasitic helminth proteins
WO1994001781A1 (fr) 1992-07-01 1994-01-20 Behring Diagnostics, Inc. Machine d'analyse automatisee comprenant un ensemble de transport de plateau de support pour echantillons de fluides
WO1994017813A1 (fr) 1993-02-08 1994-08-18 Paravax, Inc. VECTEURS DU VIRUS SINDBIS DEFECTIF QUI EXPRIMENT DES ANTIGENES P30 $i(TOXOPLASMA GONDII)
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6426050B1 (en) 1997-05-16 2002-07-30 Aurora Biosciences Corporation Multi-well platforms, caddies, lids and combinations thereof
US5910287A (en) 1997-06-03 1999-06-08 Aurora Biosciences Corporation Low background multi-well plates with greater than 864 wells for fluorescence measurements of biological and biochemical samples
US6063338A (en) 1997-06-02 2000-05-16 Aurora Biosciences Corporation Low background multi-well plates and platforms for spectroscopic measurements
US6229603B1 (en) 1997-06-02 2001-05-08 Aurora Biosciences Corporation Low background multi-well plates with greater than 864 wells for spectroscopic measurements
US6150135A (en) * 1997-05-23 2000-11-21 Heska Corporation Dirofilaria and brugia thioredoxin peroxidase type-2 (TPX-2) nucleic acid molecules, and uses thereof
US6448089B1 (en) 1999-10-12 2002-09-10 Aurora Biosciences Corporation Multiwell scanner and scanning method
US6814933B2 (en) 2000-09-19 2004-11-09 Aurora Biosciences Corporation Multiwell scanner and scanning method
US7459314B2 (en) 2003-02-13 2008-12-02 Inverness Medical Switzerland Gmbh Lateral flow immunoassay controls
DE602005023183D1 (de) 2004-07-29 2010-10-07 Relia Diagnostic Systems Llc Querstromsystem und assay
US20060051348A1 (en) 2004-09-09 2006-03-09 Jorn Gorlach Method of producing a plurality of isolated antibodies to a plurality of cognate antigens
US7387890B2 (en) 2004-12-16 2008-06-17 Chembio Diagnostic Systems, Inc. Immunoassay devices and use thereof
US7939342B2 (en) 2005-03-30 2011-05-10 Kimberly-Clark Worldwide, Inc. Diagnostic test kits employing an internal calibration system
US7976795B2 (en) 2006-01-19 2011-07-12 Rheonix, Inc. Microfluidic systems
US20100129935A1 (en) 2008-11-25 2010-05-27 Sarah Daniel Maddison Pregnancy testing method
US20100196200A1 (en) 2009-02-05 2010-08-05 Jin Po Lee Biological test strip
CN110051832B (zh) * 2019-05-31 2020-11-10 四川农业大学 一种犬恶丝虫病疫苗

Also Published As

Publication number Publication date
WO2021163448A3 (fr) 2021-11-25
AU2021218797A1 (en) 2022-08-25
EP4103225A2 (fr) 2022-12-21
BR112022015994A2 (pt) 2022-10-11
CN115209916A (zh) 2022-10-18
WO2021163448A2 (fr) 2021-08-19
JP2023513607A (ja) 2023-03-31

Similar Documents

Publication Publication Date Title
EP2640417B1 (fr) Vaccin multivalent pour la filariose
US11370814B2 (en) Vaccine and methods for detecting and preventing filariasis
Cao et al. Toxoplasma gondii: vaccination with a DNA vaccine encoding T-and B-cell epitopes of SAG1, GRA2, GRA7 and ROP16 elicits protection against acute toxoplasmosis in mice
Malkin et al. Phase 1 study of two merozoite surface protein 1 (MSP142) vaccines for Plasmodium falciparum malaria
Noe et al. A full-length Plasmodium falciparum recombinant circumsporozoite protein expressed by Pseudomonas fluorescens platform as a malaria vaccine candidate
Torben et al. Role of antibodies in Sm-p80-mediated protection against Schistosoma mansoni challenge infection in murine and nonhuman primate models
Lu et al. Alpha-galactosylceramide enhances protective immunity induced by DNA vaccine of the SAG5D gene of Toxoplasma gondii
JP6407714B2 (ja) 短縮型ｈｉｖエンベロープタンパク質（ｅｎｖ）、前記に関連する方法及び組成物
WO2013003579A1 (fr) Immunogènes inducteurs de lymphocytes t cytotoxiques pour la prévention, le traitement et le diagnostic d'une infection par le virus de la dengue
DK2134357T3 (en) nucleic acids
Caro-Aguilar et al. Chimeric epitopes delivered by polymeric synthetic linear peptides induce protective immunity to malaria
US8216593B2 (en) Parasite vaccine
US9662379B2 (en) Vaccine for falciparum malaria
WO2017011380A1 (fr) Vaccin et méthodes de dépistage et de prévention de la filariose
US20220332772A1 (en) Vaccine and methods for detecting and preventing filariasis
US20230089516A1 (en) Vaccine and Methods for Detecting and Preventing Filariasis
KR20200032169A (ko) 말라리아 백신
CA3167346A1 (fr) Vaccin et methodes de depistage et de prevention de la filariose
US20240115674A1 (en) Vaccine and methods for preventing filariasis and dirofilariasis
KR101598876B1 (ko) 리슈마니아증 및 결핵에 대한 백신 개발을 위한 ｄｎａ 키메라의 작제
US11413336B2 (en) Coccidioides antigens and methods of their use
Pirovich et al. Glycolytic Enzymes as Vaccines Against Schistosomiasis: Testing Schistosoma mansoni Phosphoglycerate Mutase in Mice
OA20058A (en) Malaria vaccine.
Pusic Immunological investigations to re-engineer a Plasmodium falciparum blood-stage human malaria vaccine
Lloyd et al. Afzal A. Siddiqui, Troy Phillips, Hugues Charest, Ron B.